The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Lung cancer
meta-analysis
prognosis
programmed cell death ligand 1
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
27
9
2019
pubmed:
27
9
2019
medline:
27
9
2019
Statut:
ppublish
Résumé
We conducted a meta-analysis to systematically evaluate the relationship between programmed death-ligand 1 (PD-L1) expression and survival in patients with lung cancer. The electronic databases PubMed, Embase, Cochrane, and Web of Science were searched up to January 2 Fifty studies including 11,383 patients published between 2011 and 2017 were enrolled in this meta-analysis. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) suggested that PD-L1 IHC expression was related to poor overall survival (OS) (HR =1.45, 95% CI: 1.24-1.68). In subgroup analysis categorized according to sample type, cut-off value, ethnicity and TNM stage, the pooled results demonstrated inferior survival in the PD-L1 positive group when the PD-L1 expression was detected by resection specimens (P=0.000), 5% was taken as the cutoff value (P=0.000), the patients were in early stage (I-III) (P=0.000), and the geographic setting of the study was in Asia (P=0.000). Besides, patients with high PD-L1 expression had shorter OS in NSCLC (P=0.000), ADC (P=0.000), SCC (P=0.353) and LELC (P=0.810), while no significant difference was observed in SCLC (P=0.000). The pooled odds ratios (ORs) suggested that PD-L1 expression was associated with male (P<0.001), smoker (P<0.001), poor tumor differentiation (P=0.014), large tumor size (P=0.132), positive lymph nodal metastasis (P=0.002), PD-L1 expression that is associated with several clinicopathological feactures may serve as a poor prognostic biomarker for patients with lung cancer.
Sections du résumé
BACKGROUND
BACKGROUND
We conducted a meta-analysis to systematically evaluate the relationship between programmed death-ligand 1 (PD-L1) expression and survival in patients with lung cancer.
METHODS
METHODS
The electronic databases PubMed, Embase, Cochrane, and Web of Science were searched up to January 2
RESULTS
RESULTS
Fifty studies including 11,383 patients published between 2011 and 2017 were enrolled in this meta-analysis. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) suggested that PD-L1 IHC expression was related to poor overall survival (OS) (HR =1.45, 95% CI: 1.24-1.68). In subgroup analysis categorized according to sample type, cut-off value, ethnicity and TNM stage, the pooled results demonstrated inferior survival in the PD-L1 positive group when the PD-L1 expression was detected by resection specimens (P=0.000), 5% was taken as the cutoff value (P=0.000), the patients were in early stage (I-III) (P=0.000), and the geographic setting of the study was in Asia (P=0.000). Besides, patients with high PD-L1 expression had shorter OS in NSCLC (P=0.000), ADC (P=0.000), SCC (P=0.353) and LELC (P=0.810), while no significant difference was observed in SCLC (P=0.000). The pooled odds ratios (ORs) suggested that PD-L1 expression was associated with male (P<0.001), smoker (P<0.001), poor tumor differentiation (P=0.014), large tumor size (P=0.132), positive lymph nodal metastasis (P=0.002),
CONCLUSIONS
CONCLUSIONS
PD-L1 expression that is associated with several clinicopathological feactures may serve as a poor prognostic biomarker for patients with lung cancer.
Identifiants
pubmed: 31555517
doi: 10.21037/tlcr.2019.08.04
pii: tlcr-08-04-429
pmc: PMC6749117
doi:
Types de publication
Journal Article
Langues
eng
Pagination
429-449Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Med Oncol. 2011 Sep;28(3):682-8
pubmed: 20373055
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Tumori. 2012 Nov;98(6):751-5
pubmed: 23389362
Eur J Cancer. 2014 May;50(7):1361-9
pubmed: 24548766
Onco Targets Ther. 2014 Apr 12;7:567-73
pubmed: 24748806
Ann Oncol. 2014 Oct;25(10):1935-40
pubmed: 25009014
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
J Thorac Oncol. 2015 Mar;10(3):426-30
pubmed: 25384063
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
Oncotarget. 2015 Feb 20;6(5):3452-61
pubmed: 25609202
Lung Cancer. 2015 Apr;88(1):24-33
pubmed: 25662388
Clin Lung Cancer. 2015 Sep;16(5):e25-35
pubmed: 25801750
Oncotarget. 2015 Jun 10;6(16):14209-19
pubmed: 25895031
J Thorac Dis. 2015 Mar;7(3):462-70
pubmed: 25922726
Lung Cancer. 2015 Aug;89(2):181-8
pubmed: 26024796
Onco Targets Ther. 2015 Jun 15;8:1451-7
pubmed: 26109869
PLoS One. 2015 Aug 27;10(8):e0136023
pubmed: 26313362
Oncotarget. 2015 Oct 20;6(32):33019-32
pubmed: 26361045
J Thorac Oncol. 2015 Dec;10(12):1726-35
pubmed: 26473645
Cancer Immunol Res. 2015 Dec;3(12):1308-15
pubmed: 26546452
Cancer Treat Rev. 2015 Dec;41(10):868-76
pubmed: 26589760
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Eur J Cancer. 2016 Mar;55:7-14
pubmed: 26771872
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Eur J Cancer. 2016 Apr;57:91-103
pubmed: 26901614
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Transl Oncol. 2016 Feb;9(1):64-69
pubmed: 26947883
Cancer Biol Ther. 2016 Apr 2;17(4):407-13
pubmed: 26954523
Oncotarget. 2016 May 31;7(22):32113-28
pubmed: 27050074
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Thorac Oncol. 2016 Jul;11(7):1003-11
pubmed: 27103510
PLoS One. 2016 Apr 22;11(4):e0153954
pubmed: 27104612
Eur J Cancer. 2016 Jun;60:125-35
pubmed: 27107327
J Hematol Oncol. 2016 May 27;9(1):47
pubmed: 27234522
Lung Cancer. 2016 Jul;97:73-80
pubmed: 27237031
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
J Transl Med. 2016 Jun 24;14(1):188
pubmed: 27342566
Lung Cancer. 2016 Aug;98:51-58
pubmed: 27393506
Lung Cancer. 2016 Aug;98:69-75
pubmed: 27393509
Oncol Lett. 2016 Aug;12(2):921-927
pubmed: 27446371
Jpn J Clin Oncol. 2016 Oct;46(10):935-941
pubmed: 27511990
Mod Pathol. 2016 Dec;29(12):1552-1564
pubmed: 27562497
J Thorac Oncol. 2016 Nov;11(11):1869-1878
pubmed: 27568346
Oncotarget. 2016 Sep 27;7(39):64318-64329
pubmed: 27602763
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
J Thorac Oncol. 2017 Mar;12(3):458-466
pubmed: 27815126
Pathol Int. 2017 Jan;67(1):37-44
pubmed: 27976463
Thorac Cancer. 2017 Mar;8(2):73-79
pubmed: 28008744
Ann Oncol. 2017 Apr 1;28(4):882-889
pubmed: 28137741
Oncotarget. 2017 Mar 7;8(10):16421-16429
pubmed: 28145884
Oncotarget. 2017 Mar 14;8(11):18021-18030
pubmed: 28152514
Lung Cancer. 2017 Feb;104:7-15
pubmed: 28213003
Oncology. 2017;92(5):283-290
pubmed: 28222447
Clin Lung Cancer. 2017 Sep;18(5):572-582.e1
pubmed: 28318951
Cancer Immunol Immunother. 2017 Jul;66(7):865-876
pubmed: 28341875
Ann Thorac Surg. 2017 Jun;103(6):1750-1757
pubmed: 28347537
Cancer Immunol Immunother. 2017 Sep;66(9):1175-1187
pubmed: 28451792
PLoS One. 2017 Jul 3;12(7):e0180346
pubmed: 28671973
J Thorac Cardiovasc Surg. 2018 Jan;155(1):382-392.e1
pubmed: 28711324
Sci Rep. 2017 Aug 31;7(1):10255
pubmed: 28860576
Oncotarget. 2017 May 29;8(31):51630-51640
pubmed: 28881674
Oncotarget. 2017 Jun 1;8(33):53978-53988
pubmed: 28903317
Cancer Med. 2017 Oct;6(10):2347-2356
pubmed: 28925087
J Thorac Dis. 2017 Aug;9(8):2579-2586
pubmed: 28932565
Oncotarget. 2017 Apr 11;8(35):58457-58468
pubmed: 28938570
Mol Diagn Ther. 2018 Feb;22(1):1-10
pubmed: 29119407
Cancer Med. 2018 Jan;7(1):32-45
pubmed: 29168339
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Mod Pathol. 2018 Sep;31(9):1381-1390
pubmed: 29713040
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Curr Opin Oncol. 2019 Jan;31(1):13-17
pubmed: 30325753
Diagn Pathol. 2018 Nov 21;13(1):91
pubmed: 30463584
J Clin Oncol. 1995 May;13(5):1221-30
pubmed: 7738625
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604